Simple Summary
Cystic renal masses range from simple benign cysts to kidney cancers with cystic features. They are being detected more often as abdominal imaging becomes increasingly common. Although some complex cystic masses require treatment, many surgically removed lesions are benign, and some malignant lesions are low-grade, confined to the kidney, and slow-growing. Current assessment focuses mainly on whether a mass is likely to be malignant, whereas how aggressively it may behave and the harm it may cause are more difficult to estimate before treatment. This Perspective reviews the range of conditions that can present as cystic renal masses, the role and limitations of the Bosniak imaging classification, and emerging applications of computer-based image analysis and artificial intelligence. It also discusses how malignancy risk, potential aggressiveness, patient health, kidney function, and individual preferences may be considered together when selecting surveillance or intervention.
Abstract
Cystic renal masses (CRMs) encompass a broad spectrum of conditions ranging from simple renal cysts to cystic renal cell carcinoma. Their detection has increased markedly with the widespread use of abdominal imaging, raising concern about potential overtreatment: many complex CRMs treated surgically are ultimately benign, while some malignant lesions are low grade, localized, and follow a relatively indolent clinical course. Although the Bosniak classification stratifies malignancy probability, translating lesion characteristics into preoperative assessments of biological aggressiveness and patient-specific clinical consequences remains challenging. Drawing on published evidence and common clinical decision-making scenarios, this Perspective outlines the pathologic classification of CRMs, examines the limitations of the Bosniak classification, and discusses the prospects for and current barriers to the use of radiomics and artificial intelligence for benign-versus-malignant classification. With the dual objectives of differentiating benign from malignant lesions and assessing biological aggressiveness, we focus on individualized management strategies that integrate the probability of malignancy, potential clinical harm, and patient-specific factors. These strategies include conservative management, indications for surgery, and selection of surgical approach. The aim is to inform more standardized and precise diagnosis and management of CRMs.